Hospital Clinic Barcelona, IDIBAPS, CIBEREHD, University of Barcelona, Barcelona, Spain.
Curr Opin Organ Transplant. 2010 Dec;15(6):685-90. doi: 10.1097/MOT.0b013e3283402c55.
To describe most relevant data regarding strategies to achieve immunosuppression minimization and/or complete withdrawal in liver transplantation and to discuss the development of tolerance biomarkers to predict the success of immunosuppression weaning.
In clinical organ transplantation allograft tolerance has been attained through two different pathways: (1) tolerance or immunosuppression minimization has been attempted by administering induction therapies with or without infusion of donor hematopoietic cells; and (2) the availability of spontaneously tolerant liver and kidney recipients has been exploited to develop biomarkers of allograft tolerance. The use of transcriptional profiling is the most promising approach. Recent publications have identified a gene expression signature in tolerant patients.
Current immunosuppressive regimens reduce acute rejection episodes but promote a number of complications that have a negative impact on patient morbidity, mortality and quality of life. In this setting, achievement of tolerance is a major goal. Although there are no reliable markers to identify tolerant patients, recent studies have found that tolerant liver recipients exhibit unique peripheral blood transcriptional patterns. The difference in expression patterns is related to the immune response and could constitute the basis of a future diagnostic test of tolerance.
描述肝移植中实现免疫抑制最小化和/或完全撤除的最相关数据,并讨论预测免疫抑制撤药成功的耐受生物标志物的发展。
在临床器官移植中,同种异体移植物的耐受已经通过两种不同的途径实现:(1)通过给予诱导治疗,同时或不输注供体造血细胞,尝试耐受或免疫抑制最小化;(2)利用自发耐受的肝和肾受者,开发移植物耐受的生物标志物。转录谱分析是最有前途的方法。最近的出版物已经在耐受患者中确定了一个基因表达特征。
目前的免疫抑制方案减少了急性排斥反应的发生,但也促进了许多并发症的发生,这些并发症对患者的发病率、死亡率和生活质量产生了负面影响。在这种情况下,实现耐受是一个主要目标。尽管目前还没有可靠的标志物来识别耐受患者,但最近的研究发现,耐受的肝移植受者表现出独特的外周血转录模式。表达模式的差异与免疫反应有关,可能成为未来耐受诊断测试的基础。